.webp)
Principal Consultant
Reviewed By
The global biospecimen procurement market size is calculated at US$ 85.94 in 2024, grew to US$ 99.72 million in 2025, and is projected to reach around US$ 380.42 million by 2034. The market is expanding at a CAGR of 16.04% between 2025 and 2034.
For ideal evaluation of proteome, genome, and transcriptome, the preserved frozen biospecimens are often used. The process of obtaining biospecimens such as fresh tissue samples, whole blood samples, FFPE tissue blocks, etc., for life science research and development studies is known as biospecimen procurement. Biospecimen procurement consists of various steps, like identification of biospecimen providers containing the sample of interest, ordering the samples, monitoring the sample collected, and shipping the samples. The biospecimen procurement can also be carried out by setting up the studies with clinicians that use hospital or university biobanks or by using biospecimens from commercial companies.
| Metric | Details |
| Market Size in 2024 | USD 85.94 Million |
| Projected Market Size in 2034 | USD 380.42 Million |
| CAGR (2025 - 2034) | 16.04% |
| Leading Region | North America |
| Market Segmentation | By Therapeutic Area, By Type of Biospecimen for Oncological Studies, By Type of Biospecimen for Non-Oncological Studies, By Region |
| Top Key Players |
Creative Bioarray, BioChain Institute, Discovery Life Sciences, BioIVT, National BioService, PrecisionMed, Infinity BiologiX, Medicove, REPROCELL, Precision for Medicine |
By utilizing AI and ML algorithms, the biospecimen procurement can be transformed as they help in the optimization of the selection and characterization processes. These AI algorithms can identify potential donors by analyzing immense volumes of data, such as genetic information and patient records, and help to match them as per the research needs with efficiency and accuracy. The sorting and classification of biospecimens are also carried out using these algorithms based on different criteria like a genetic profile or disease type, streamlining the procurement process and facilitating targeted research initiatives. The biospecimen management and consideration of the right specimens that are procured and utilized for research purposes can be enhanced by integrating AI & ML with the Laboratory Information Management System (LIMS).
Rising Chronic Diseases
The incidences of chronic diseases are increasing. Thus, to provide more treatment and diagnostic options, research in various industries and institutes is rising. This increases the demand for biospecimens as they can be used to identify the biomarkers that help in developing target-specific drugs. Furthermore, they are also required in clinical trials for testing for toxicological studies as well as in assessing the medication’s efficacy. Moreover, they are also used in the development of various biologics and biosimilars. Thus, as the chronic disease rate rises, the demand for biospecimen procurement ultimately rises, which enhances the biospecimen procurement market growth.
The graph indicates the estimated rates of patients affected with chronic diseases in the year 2025 and 2030. It indicates that as the number of patients increases, the requirement for diagnostic and treatment options will also increase, which in turn will raise the need for biospecimen procurement. Furthermore, researchers can focus on developing better treatment options by using biospecimens, which will ultimately promote the market's growth.
Limited Access
The availability of biospecimens for diseases such as rare diseases is limited. This, in turn, makes the biospecimens difficult to obtain for the studies. This may be due to the difficulty faced during the recruitment of suitable patients as donors for biospecimens. Similarly, their storage, maintenance, and transportation are also difficult, due to which the access to the biospecimens gets hampered. Furthermore, the increased cost can also affect biospecimen procurement.
Increasing Gene Therapies
Gene therapies have shown successful treatment in various patients for different diseases. This, in turn, has increased the development of new gene therapies for the personalized treatment of diseases like genetic disorders, oncology, neurological diseases, etc. Furthermore, the use of technological advancement has also enhanced the development process. This, in turn, increased the need for biospecimen procurement. Thus, these biospecimens were used in gene therapy development at various stages, which included the analysis of the biomarkers to the toxicological studies in the clinical trials. Thus, this ultimately increases the biospecimen procurement market growth.
For instance,
By therapeutic area type, the oncological disorders segment dominated the market in 2024. The rising incidences of cancer increased the demand for treatment options, which in turn increased the requirement for biospecimen procurement. Thus, with the help of biospecimen procurement identification of biomarkers and gene therapies was developed. This increased the biospecimen procurement market growth.
By type of biospecimen for oncological studies, the FFPE segment dominated the market in 2024. The FFPE biospecimen showed long-term stabilities. This enhanced their use in gene therapy. Furthermore, their use increased in cancer diagnosis as well as in the development of personalized therapies, which in turn increased the requirement for biospecimen procurement.
By type of biospecimen for non-oncological studies, the blood product segment dominated the global biospecimen procurement market in 2024. The blood product biospecimens were readily available for various research for the treatment of diseases. At the same time, their applications in various diseases as well as affordability increased their demand in the market.
North America dominated the biospecimen procurement market in 2024. North America consists of well-developed research and development sectors in various industries. These industries were further associated with healthcare sectors and institutes to carry out various research. This increased the research in life science, which enhanced the demand for biospecimens procurement, which in turn was supported by the government. All these factors contributed to the market growth.
The presence of a large number of industries increases the amount of research carried out. This increases the demand for biospecimen procurement for various studies. At the same time, increased clinical trials enhance the procurement of biospecimens from the biobanks that are integrated with them.
The advanced research and development sector in Canada is increasing the use of biospecimens for various treatment research. Thus, this has increased the collaborations of industries with the biobanks to make the biospecimens easily available. It is further supported by the government’s funding.
Asia Pacific is estimated to host the fastest-growing biospecimen procurement market during the forecast period. Asia Pacific is experiencing rapid development in the pharmaceutical and biotechnological industries. This, in turn, is increasing the research and clinical trials on various treatment and diagnostic options. Thus, this is enhancing the need for biospecimen procurement through various biobanks, which is promoting market growth.
The number of industries in China is increasing along with the technological advancements. At the same time, the demand for gene therapies and personalized medications is also increasing. Thus, all these factors are growing the demand for biospecimen procurement.
The number of industries and startups in India is rising. At the same time, the increasing number of diseases is driving interest in research as well as clinical trials. This increases the use of biospecimens. Thus, various biobanks are being developed to store, manage, and distribute the proper biospecimens to the clients.
Europe is expected to grow significantly in the biospecimen procurement market during the forecast period. Due to increasing diseases, the demand for treatment is also increasing. At the same time, increased awareness about personalized medication and gene therapies is also contributing to the same. Thus, the biospecimen procurement is increasing to develop new treatment options for the diseases, which in turn is enhancing the market growth.
Biospecimen procurement is rising due to increased research for various diseases such as oncology. This procurement is becoming easier and faster because of the presence of biobanks along with technological advancements. Furthermore, the strong regulatory framework also enhances biospecimen procurement.
As the demand for treatment using personalized or gene therapy is increasing, the use of biospecimens is also increasing. Furthermore, to deal with the increasing need for biospecimen, various companies are collaborating together as well as with the biobanks. It is further supported by the funding provided by the government.
By Therapeutic Area
By Type of Biospecimen for Oncological Studies
By Type of Biospecimen for Non-Oncological Studies
By Region
Schedule a Meeting
Download Brochure
Table of Content